Stockreport

FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF TARRYTOWN, N.Y. and PARIS, June 26, 2019 /PRNewswire/ -- First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRS [Read more]